Naloxone Hydrochloride
Sponsors
Sydvestjysk Sygehus, Dana-Farber Cancer Institute, Finnish Institute for Health and Welfare, University of California, San Francisco, Opiant Pharmaceuticals Inc
Conditions
Chronic Opioid UseChronic Pain SyndromeConstipation, Impaction, and Bowel ObstructionFentanyl OverdoseFentanyl PoisoningGambling DisorderNaloxoneObesity and
Obstructive Sleep apnoea
Phase 1
The Effect of Chronic Pain on Delay Discounting in Methadone Patients
TerminatedNCT04473950
Start: 2020-01-08End: 2022-10-06Updated: 2025-03-26
Pharmacodynamic Evaluation of Intranasal Nalmefene
CompletedNCT04828005
Start: 2021-03-30End: 2022-03-14Updated: 2025-07-14
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
RecruitingNCT05338632
Start: 2022-06-24End: 2026-10-01Target: 24Updated: 2025-01-31
Phase 2
Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder
NCT03430180
Start: 2018-02-22End: 2020-03-30Target: 126Updated: 2019-07-16
MORPHINE PHARMACOKINETICS AND –DYNAMICS IN HEALTHY VOLUNTEERS AND PATIENTS WITH OBESITY AND OBSTRUCTIVE SLEEP APNOEA.
-AN INVESTIGATOR INITIATED, CLINICAL STUDY OF THE IMPACT OF OBESITY AND SLEEP APNOEA ON THE PHARMACOLOGY OF MORPHINE
CompletedCTIS2022-500779-29-00
Start: 2022-12-01End: 2025-12-16Target: 140Updated: 2025-12-16
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
Not yet recruitingNCT07459166
Start: 2026-04-01End: 2026-10-01Target: 16Updated: 2026-03-27